Abnormal melt curve profile during prothrombin 20210G → A analysis due to the 20209C → T variant

The common factor II 20210G → A mutation, located in the 3′-untranslated region, is an important risk factor for the development of thromboembolic disorders, especially in Caucasians. A number of methods are employed for clinical laboratory diagnosis of this mutation, some of which are capable of detecting adjacent 3′-end sequence variations. We present results from an African deep vein thrombosis patient tested for the 20210G → A mutation by real-time polymerase chain reaction and melt-curve analysis using hybridization probes that incidentally detected an adjacent 3′-untranslated region variant. The patient sample was tested using the Factor II (Prothromobin) G20210A Kit (Roche Diagnostics, Indianapolis, Indiana, USA), in conjunction with the Roche LightCycler. A polymerase chain reaction fragment from the 3′-end of the F2 gene was subsequently sequenced for identification of the variant. Melt-curve analysis revealed a normal 20210*G peak and an unknown aberrant allelic peak. Following sequence analysis, the patient was determined to be heterozygous for 20209C → T. The presence of the 20209C → T variant in the current patient and in eight other reported individuals of African descent, most with thrombosis-associated complaints, suggests that this rare variant poses a potential increased risk for thromboembolic disease in this ethnic group.

[1]  A. Gressner,et al.  Atypical melting curve resulting from genetic variation in the 3' untranslated region at position 20218 in the prothrombin gene analyzed with the LightCycler factor II (prothrombin) G20210A assay. , 2005, Clinical chemistry.

[2]  S. Thein,et al.  Detection of prothrombin gene polymorphism at position 20209 (PT20209C/T): Pilot study in a black population in the United Kingdom , 2005, Thrombosis and Haemostasis.

[3]  M. Hentze,et al.  The prothrombin 3'end formation signal reveals a unique architecture that is sensitive to thrombophilic gain-of-function mutations. , 2004, Blood.

[4]  C. C. Spaargaren-van Riel,et al.  G20210A is a functional mutation in the prothrombin gene; effect on protein levels and 3′‐end formation , 2004, Journal of thrombosis and haemostasis : JTH.

[5]  J. Zehnder,et al.  Prothrombin gene variants in non-Caucasians with fetal loss and intrauterine growth retardation. , 2003, The Journal of molecular diagnostics : JMD.

[6]  B. Kosova,et al.  Budd–Chiari syndrome in a patient heterozygous for the point mutation C20221T of the prothrombin gene , 2003, Journal of thrombosis and haemostasis : JTH.

[7]  J. Zehnder,et al.  Consultations in Molecular Diagnostics Prothrombin Gene Variants in Non-Caucasians with Fetal Loss and Intrauterine Growth Retardation , 2003 .

[8]  K. Kottke-Marchant,et al.  Detection of a Novel Point Mutation of the Prothrombin Gene at Position 20209 , 2002, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[9]  E. Pollak,et al.  The G20210A mutation does not affect the stability of prothrombin mRNA in vivo. , 2002, Blood.

[10]  Matthias W. Hentze,et al.  Increased efficiency of mRNA 3′ end formation: a new genetic mechanism contributing to hereditary thrombophilia , 2001, Nature Genetics.

[11]  K. Wielckens,et al.  A Novel Point Mutation in the 3’ Region of the Prothrombin Gene at Position 20221 in a Lebanese/Syrian Family , 2001, Thrombosis and Haemostasis.

[12]  N. Wenger,et al.  Prevalence of the prothrombin 20210 G-to-A variant in blacks: infants, patients with venous thrombosis, patients with myocardial infarction, and control subjects. , 1998, The Journal of laboratory and clinical medicine.

[13]  P. Reitsma,et al.  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. , 1996, Blood.